Metabolic & Endocrine
Overweight and Obesity
1
Pipeline Programs↗
4
Active Trials↗
3
Companies Involved↗
Overweight and Obesity is an early-stage landscape with 1 program across 3 companies. The most active players are AstraZeneca, Eli Lilly, Midwest Center for Metabolic and Cardiovascular Research.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
11
clinical trials
Completed7 · 64%
Recruiting2 · 18%
Enrolling by invitation1 · 9%
Active, not recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
A Randomized, Parallel Trial to Assess the Effects of Replacing Non-fermented, Non-dairy Foods With Full-fat or Low-fat Fermented Dairy Foods on Insulin Sensitivity, RBC FA's and Other Markers of Cardiometabolic Health
Completed·MMidwest Center for Metabolic and Cardiovascular Research·Preclinical·NCT04999462·110 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)